BRIVIACT® offers a therapeutic dose on DAY ONE
The recommended starting dose for monotherapy and adjunctive therapy is 50 mg twice daily (100 mg/day) and is initiated without titration1
Gradual dose escalation is not required with BRIVIACT
- Based on individual patient response, the dose may be adjusted between 25 mg twice daily (50 mg/day) and 100 mg twice daily (200 mg/day)
- Avoid abrupt withdrawal from BRIVIACT in order to minimize the risk of increased seizure frequency and status epilepticus
Dosing in specific populations
- For all stages of hepatic impairment, the recommended starting dosage is 25 mg twice daily (50 mg/day) and the recommended maximum dosage is 75 mg twice daily (150 mg/day)
- Dose adjustments are not required for patients with impaired renal function; there are no data in patients with end-stage renal disease undergoing dialysis, and use of BRIVIACT is not recommended in this patient population
BRIVIACT® is available in multiple formulations, allowing for dosing flexibility
Considerations for tablets and oral solution1
- BRIVIACT can be given with or without food
- Tablets should be swallowed whole with liquid; they should not be chewed or crushed; tablets are not scored
Considerations for intravenous (IV) use*1
BRIVIACT injection may be used when oral administration is temporarily not feasible.
- BRIVIACT injection can be administered intravenously without further dilution or may be mixed with diluents listed below:
- 0.9% sodium chloride injection, USP
- Lactated Ringer's injection
- 5% dextrose injection, USP
- BRIVIACT injection should be administered intravenously over 2 to 15 minutes
Adverse reactions with BRIVIACT injection are generally similar to those observed with BRIVIACT tablets and also include dysgeusia, euphoric mood, feeling drunk, and infusion site pain.
†10-mg tablets are available for down titration.
- No blood-level monitoring required
- Approximately 100% oral bioavailability
- Linear pharmacokinetics
- The half-life (t1/2) is approximately 9 hours, steady-state reached after 2 days
- BRIVIACT is weakly bound (≤20%) to plasma proteins
- No pharmacologically active metabolites
- *Clinical study experience limited to 4 consecutive days of treatment.